Since the introduction of durable left ventricular assist devices for advanced heart failure, management of antithrombotic medications has been the single most pivotal facet of the care of patients with these devices. As the devices have evolved — from pulsatile to continuous and from axial flow to centrifugal — much has been learned about the appropriate intensity of antithrombotic